MARKSANS — Marksans Pharma Income Statement
0.000.00%
Last trade - 00:00
- IN₹78.99bn
- IN₹73.59bn
- IN₹18.52bn
- 88
- 16
- 97
- 80
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10,001 | 11,342 | 13,762 | 14,908 | 18,521 |
Cost of Revenue | |||||
Gross Profit | 4,633 | 5,429 | 7,576 | 7,428 | 9,308 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8,907 | 9,686 | 10,727 | 12,767 | 15,536 |
Operating Profit | 1,093 | 1,656 | 3,035 | 2,141 | 2,985 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,043 | 1,572 | 3,022 | 2,475 | 3,377 |
Provision for Income Taxes | |||||
Net Income After Taxes | 804 | 1,208 | 2,385 | 1,868 | 2,653 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 765 | 1,170 | 2,359 | 1,846 | 2,663 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 765 | 1,170 | 2,359 | 1,846 | 2,663 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.94 | 2.97 | 5.88 | 4.51 | 6.42 |
Dividends per Share |